In Enterobacterales bacteremia, antipseudomonal β-lactam de-escalation was noninferior to continuation for clinical cure at 3 to 5 d

Konstantinos Ouranos; Eleftherios Mylonakis

doi:10.7326/J24-0030

In Enterobacterales bacteremia, antipseudomonal β-lactam de-escalation was noninferior to continuation for clinical cure at 3 to 5 d

Ann Intern Med. 2024 May;177(5):JC52. doi: 10.7326/J24-0030. Epub 2024 May 7.

Authors

Konstantinos Ouranos¹, Eleftherios Mylonakis¹

Affiliation

¹ Houston Methodist Hospital, Houston, Texas, USA (K.O., E.M.).

PMID: 38710092
DOI: 10.7326/J24-0030

Abstract

López-Cortés LE, Delgado-Valverde M, Moreno-Mellado E, et al; SIMPLIFY study group. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial. Lancet Infect Dis. 2024;24:375-385. 38215770.

Publication types

Multicenter Study
Randomized Controlled Trial

MeSH terms

Aged
Anti-Bacterial Agents* / therapeutic use
Bacteremia* / drug therapy
Drug Administration Schedule
Enterobacteriaceae / drug effects
Enterobacteriaceae Infections* / drug therapy
Female
Humans
Male
Middle Aged
beta-Lactams* / therapeutic use